
Sasithon Pukrittayakamee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8413292/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
2	Malaria. Lancet, The, 2014, 383, 723-735.	13.7	935
3	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	21.4	515
4	Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infectious Diseases, The, 2015, 15, 415-421.	9.1	363
5	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science, 2015, 347, 431-435.	12.6	362
6	Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases, The, 2019, 19, 952-961.	9.1	252
7	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infectious Diseases, The, 2019, 19, 943-951.	9.1	219
8	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	13.7	182
9	Therapeutic Responses to Different Antimalarial Drugs in Vivax Malaria. Antimicrobial Agents and Chemotherapy, 2000, 44, 1680-1685.	3.2	164
10	Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes. Blood, 2015, 125, 1314-1324.	1.4	157
11	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 61-69.	9.1	147
12	Activities of Artesunate and Primaquine againstAsexual- and Sexual-Stage Parasites in FalciparumMalaria. Antimicrobial Agents and Chemotherapy, 2004, 48, 1329-1334.	3.2	136
13	Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 324-327.	1.8	114
14	The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. PLoS Medicine, 2019, 16, e1002745.	8.4	105
15	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
16	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infectious Diseases, The, 2020, 20, 1470-1480.	9.1	94
17	Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. New England Journal of Medicine, 2016, 375, 1152-1160.	27.0	89
18	Malaria ecology along the Thailand–Myanmar border. Malaria Journal, 2015, 14, 388.	2.3	86

#	Article	IF	CITATIONS
19	The role of early detection and treatment in malaria elimination. Malaria Journal, 2016, 15, 363.	2.3	82
20	Pharmacokinetic Interactions between Primaquine and Chloroquine. Antimicrobial Agents and Chemotherapy, 2014, 58, 3354-3359.	3.2	78
21	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	7.1	78
22	Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Tropica, 2004, 89, 351-356.	2.0	74
23	Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. BMC Medicine, 2017, 15, 117.	5.5	62
24	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. ELife, 2021, 10, .	6.0	53
25	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
26	Village malaria worker performance key to the elimination of artemisinin-resistant malaria: a Western Cambodia health system assessment. Malaria Journal, 2016, 15, 282.	2.3	48
27	Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 7340-7346.	3.2	42
28	Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 505-513.	3.2	41
29	Laboratory Detection of Artemisinin-Resistant Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2014, 58, 3157-3161.	3.2	40
30	Quantifying Low Birth Weight, Preterm Birth and Small-for-Gestational-Age Effects of Malaria in Pregnancy: A Population Cohort Study. PLoS ONE, 2014, 9, e100247.	2.5	40
31	Estimating Gestational Age in Late Presenters to Antenatal Care in a Resource-Limited Setting on the Thai-Myanmar Border. PLoS ONE, 2015, 10, e0131025.	2.5	36
32	A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. British Journal of Clinical Pharmacology, 2001, 52, 655-661.	2.4	33
33	Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes. PLoS ONE, 2017, 12, e0172718.	2.5	33
34	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	4.4	33
35	A Comparison of Two Short-Course Primaquine Regimens for the Treatment and Radical Cure of Plasmodium vivax Malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 2010, 82, 542-547.	1.4	32
36	Safety, Pharmacokinetics, and Mosquito‣ethal Effects of Ivermectin in Combination With Dihydroartemisininâ€Piperaquine and Primaquine in Healthy Adult Thai Subjects. Clinical Pharmacology and Therapeutics, 2020, 107, 1221-1230.	4.7	30

#	Article	IF	CITATIONS
37	Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	29
38	Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. American Journal of Tropical Medicine and Hygiene, 2008, 79, 378-84.	1.4	29
39	Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers. British Journal of Clinical Pharmacology, 2017, 83, 2752-2766.	2.4	28
40	Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLoS ONE, 2018, 13, e0198695.	2.5	27
41	Gestational diabetes mellitus prevalence in Maela refugee camp on the Thai–Myanmar Border: a clinical report. Clobal Health Action, 2014, 7, 23887.	1.9	25
42	The Diversity and Geographical Structure of Orientia tsutsugamushi Strains from Scrub Typhus Patients in Laos. PLoS Neglected Tropical Diseases, 2015, 9, e0004024.	3.0	25
43	The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. British Journal of Clinical Pharmacology, 1996, 41, 29-34.	2.4	21
44	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. Journal of Infectious Diseases, 2019, 220, 1178-1187.	4.0	21
45	Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs. Journal of Antimicrobial Chemotherapy, 2018, 73, 3102-3113.	3.0	20
46	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. PLoS Medicine, 2020, 17, e1003040.	8.4	20
47	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and nonâ€obese volunteers. British Journal of Clinical Pharmacology, 2016, 81, 1103-1112.	2.4	19
48	The pituitary-thyroid axis in severe falciparum malaria: evidence for depressed thyrotroph and thyroid gland function. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 330-335.	1.8	18
49	The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin–piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal, 2018, 17, 405.	2.3	18
50	Challenges arising when seeking broad consent for health research data sharing: a qualitative study of perspectives in Thailand. BMC Medical Ethics, 2018, 19, 86.	2.4	18
51	Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. Journal of Infectious Diseases, 2019, 220, 448-456.	4.0	17
52	An Open-Label Crossover Study To Evaluate Potential Pharmacokinetic Interactions between Oral Oseltamivir and Intravenous Zanamivir in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2011, 55, 4050-4057.	3.2	14
53	A Population Survey of the Glucose-6-Phosphate Dehydrogenase (G6PD) 563C>T (Mediterranean) Mutation in Afghanistan. PLoS ONE, 2014, 9, e88605.	2.5	13
54	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13

#	Article	IF	CITATIONS
55	Genetic polymorphisms in the circumsporozoite protein of Plasmodium malariae show a geographical bias. Malaria Journal, 2018, 17, 269.	2.3	12
56	Miscarriage, stillbirth and neonatal mortality in the extreme preterm birth window of gestation in a limited-resource setting on the Thailand-Myanmar border: A population cohort study. Wellcome Open Research, 2016, 1, 32.	1.8	11
57	Impact of glucose-6-phosphate dehydrogenase deficiency on dengue infection in Myanmar children. PLoS ONE, 2019, 14, e0209204.	2.5	10
58	Genetic diversity of three surface protein genes in Plasmodium malariae from three Asian countries. Malaria Journal, 2018, 17, 24.	2.3	9
59	Acidosis and acute kidney injury in severe malaria. Malaria Journal, 2018, 17, 128.	2.3	9
60	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
61	Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. Human Vaccines and Immunotherapeutics, 2020, 16, 33-41.	3.3	9
62	Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. Malaria Journal, 2016, 15, 121.	2.3	8
63	Prevalence and clinical manifestations of dengue in older patients in Bangkok Hospital for Tropical Diseases, Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 674-681.	1.8	8
64	Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy. PLoS ONE, 2016, 11, e0159347.	2.5	8
65	The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos. Malaria Journal, 2019, 18, 449.	2.3	7
66	Cohort profile: molecular signature in pregnancy (MSP): longitudinal high-frequency sampling to characterise cross-omic trajectories in pregnancy in a resource-constrained setting. BMJ Open, 2020, 10, e041631.	1.9	6
67	Predictive model of return of spontaneous circulation among patients with outâ€ofâ€hospital cardiac arrest in Thailand: The WATCH PR Score. International Journal of Clinical Practice, 2020, 74, e13502.	1.7	6
68	Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparumÂhave only a transient impact on Plasmodium vivax: Findings from randomised controlled trials. PLoS ONE, 2020, 15, e0228190.	2.5	6
69	Limited Polymorphism of the Kelch Propeller Domain in Plasmodium malariae and P. ovale Isolates from Thailand. Antimicrobial Agents and Chemotherapy, 2016, 60, 4055-4062.	3.2	4
70	Assessment <i>In Vitro</i> of the Antimalarial and Transmission-Blocking Activities of Cipargamin and Ganaplacide in Artemisinin-Resistant <i>Plasmodium falciparum</i> . Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0148121.	3.2	4
71	Rickettsial Infections Are Neglected Causes of Acute Febrile Illness in Teluk Intan, Peninsular Malaysia. Tropical Medicine and Infectious Disease, 2022, 7, 77.	2.3	4
72	Estimating the programmatic cost of targeted mass drug administration for malaria in Myanmar. BMC Public Health, 2021, 21, 826.	2.9	3

#	Article	IF	CITATIONS
73	Diagnosis of Murine Typhus by Serology in Peninsular Malaysia: A Case Report Where Rickettsial Illnesses, Leptospirosis and Dengue Co-Circulate. Tropical Medicine and Infectious Disease, 2019, 4, 23.	2.3	2
74	Detecting geospatial patterns of Plasmodium falciparum parasite migration in Cambodia using optimized estimated effective migration surfaces. International Journal of Health Geographics, 2020, 19, 13.	2.5	2
75	Genetic analysis of the orthologous crt and mdr1 genes in Plasmodium malariae from Thailand and Myanmar. Malaria Journal, 2020, 19, 315.	2.3	1
76	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
77	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	4.0	1